Cancel
NexImmune
NexImmune Employees
8 people indexed:
-
Daniel Bednarik Ph.D.
Senior Vice President, Molecular Engineering & Protein Design
53g0s7t39.6z.l@t7682flwj.l92 Sign up to see emailv08y7fqzv.wj.4@y990ysj3f.wfs Sign up to see email -
vv6w8w6@dws4q0sq8.l28 Sign up to see email
-
2t3f7qvfz@4yw6wv8tz.p6d Sign up to see email
-
q130f8@h3l98hhg5.vrz Sign up to see email
-
96bv5j.77.9@2z2690v05.z8w Sign up to see email
-
58vjw67v2@22gqwd1d6.gdj Sign up to see email
-
fdj246y@ay39yh2pf.w45 Sign up to see email
-
s0z49j1jjy@88vfg327s.31b Sign up to see email
NexImmune Company Information
NexImmune is a biotechnology firm based in Gaithersburg, MD, specializing in the development of novel technologies that harness natural biology to control and direct the body’s immune response to fight a wide range of diseases. The company’s proprietary AIM™ technology platforms, including AIM™ NT Platform, AIM™ ACT Adoptive Cellular Therapy, and AIM™ INJ Direct Injection, enable customization of immune responses, either intensifying or dampening them, to treat conditions such as cancer, infectious diseases, and autoimmune disorders. Recently, NexImmune raised $3.67 million through a registered direct offering priced at-the-market under Nasdaq rules. Additionally, the company has extended its research partnership with Yale and JDRF to further explore treatments for Type 1 Diabetes.
Report inaccurate information
Report inaccurate information
